Raiffeisen Bank International AG Grows Stake in Medtronic PLC $MDT

Raiffeisen Bank International AG boosted its holdings in shares of Medtronic PLC (NYSE:MDT) by 18.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 42,344 shares of the medical technology company’s stock after purchasing an additional 6,673 shares during the quarter. Raiffeisen Bank International AG’s holdings in Medtronic were worth $3,979,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Riverbend Wealth Management LLC raised its position in shares of Medtronic by 3.2% during the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after buying an additional 107 shares during the last quarter. Holistic Financial Partners increased its holdings in Medtronic by 3.0% in the 3rd quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock valued at $352,000 after acquiring an additional 109 shares during the last quarter. Wynn Capital LLC lifted its stake in Medtronic by 2.4% in the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock worth $442,000 after purchasing an additional 110 shares in the last quarter. Meridian Investment Counsel Inc. boosted its holdings in shares of Medtronic by 0.4% during the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock valued at $2,692,000 after purchasing an additional 110 shares during the last quarter. Finally, Saxony Capital Management LLC boosted its holdings in shares of Medtronic by 3.8% during the 3rd quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after purchasing an additional 112 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

Shares of Medtronic stock opened at $96.88 on Friday. The stock has a market cap of $124.20 billion, a price-to-earnings ratio of 26.99, a price-to-earnings-growth ratio of 2.43 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The stock has a 50 day moving average price of $99.04 and a 200-day moving average price of $96.70. Medtronic PLC has a one year low of $79.55 and a one year high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.Medtronic’s revenue was up 5.8% on a year-over-year basis. During the same period last year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. Medtronic’s payout ratio is currently 79.11%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. TD Cowen restated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Leerink Partners reduced their price objective on Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a research note on Wednesday. Daiwa Securities Group increased their target price on Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $110.00 target price on shares of Medtronic in a report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, Medtronic currently has an average rating of “Moderate Buy” and a consensus price target of $110.84.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Regulatory/coverage win in Japan for Medtronic’s Symplicity Spyral renal denervation device and management commentary that the company is investing in rollout and hiring to support market development — supports revenue upside from a growing hypertension therapy. Medtronic’s blood pressure device wins coverage nod in Japan
• Positive Sentiment: Analyst upgrade: Mizuho moved Medtronic to a “strong-buy,” which can support buying interest and short-term momentum. Mizuho upgrade reported via Zacks
• Neutral Sentiment: Industry growth tailwinds — a separate report highlights expansion in non‑invasive therapies (HIFU) and robotics/image‑guided systems; positive for device sector demand but not a direct Medtronic headline. HIFU Market Competitive Landscape Report 2025
• Neutral Sentiment: Competitive update — Intuitive Surgical (ISRG) reports faster international procedure growth, which underscores competitive dynamics in robotics and could pressure Medtronic’s robotics expectations over time. ISRG’s International Growth Outpaces US
• Neutral Sentiment: Company commentary and Q3 earnings materials are out (transcript available) showing mixed results: solid robotics wins but offset by some legal and expense items — provides context for guidance and valuation debate. Medtronic (MDT) Q3 2026 Earnings Call Transcript
• Negative Sentiment: Multiple broker notes lowered expectations or targets (JPMorgan, Robert W. Baird; Leerink cut its target to $119) — analyst downgrades/target cuts weigh on sentiment and can amplify selling. JPMorgan low expectations
• Negative Sentiment: Planned layoffs: Medtronic will cut 81 roles at a California diabetes site as it readies the diabetes spin‑out; restructuring adds near‑term execution risk and uncertainty around the separations. Medtronic to cut 81 employees at California diabetes site
• Negative Sentiment: Broader skepticism in media pieces discussing mixed quarterly results, legal exposure and whether recent wins materially change Medtronic’s investment case — fuels analyst disagreement and investor caution. Mixed Q3 Results, Robotics Win and Legal Hit

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).